Journal article

Central nervous system multiple myeloma - potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains

Denise Lee, Anna Kalff, Michael Low, Shane Gangatharan, Prahlad Ho, Ashish Bajel, David Ritchie, Andrew Grigg, Andrew Spencer

BRITISH JOURNAL OF HAEMATOLOGY | WILEY | Published : 2013

Abstract

Central nervous system (CNS) multiple myeloma (MM) is exceedingly rare and portends a dismal prognosis. While immunomodulators have contributed to the improvement in survival in MM, they appear to have limited activity against CNS MM and, paradoxically, may contribute to the evolution of resistant MM clones capable of surviving within the CNS. We undertook a retrospective analysis to characterize the features of CNS MM and outcome in 17 patients from four institutions identified between 2000 and 2011. The median age was 58 years. Patients had received a median of three prior therapies and all had been exposed to at least one of the so-called novel anti-MM agents before the diagnosis of CNS M..

View full abstract